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Summary.-This paper reports the prognostic significance of clinical and laboratory
features recorded at presentation in 485 patients entered into the Medical Research
Council's 3rd therapeutic trial in myelomatosis between July 1975 and August 1978.
The data were complete up to 1 January 1980, with a median follow-up time of 36
months.
The 3 major determinants of prognosis were the blood urea concentration (BUC),
the haemoglobin concentration ([Hb]), and the clinical performance status. Three
prognostic groups based on these determinants were specified. The groups contained
220/o, 56% and 220% of the patients and gave 2-year survival probabilities of 760, 5000/
and 9O/ respectively. Patients in the good-prognosis group had a BUC .8 mM.
lHb] > 100 g/l, and no or minimal symptoms. Those in the poor-prognosis group had
either [Hb] <75 g/l or a BUC > 10 mM and restricted clinical activity. Patients who had
combinations of the 3 determinant features which excluded them from these 2 groups
were classified into an intermediate prognosis group.
STAGING SYSTEMS like that used in
Hodgkin's disease are being increasingly
applied to haemopoietic neoplasms be-
cause of their prognostic value. In myelo-
matosis Durie & Salmon (1975) have
defined 3 stages based on estimates of the
total tumour burden. A more direct
approach is to ask which combination of
features recorded at the time of presenta-
tion best predict survival. This is the
approach we and others (Costa et al., 1]973;
S.E. Cancer Study Group, 1975; Matzner
et al., 1978) have used. Our approach
involves the direct correlation of present-
ing features with survival and has led Us
to devise a simple classification procedure
based upon 3 factors: renal function
(blood urea concentration (BUC) after
hydration), anaemia (haemoglobin (Hb)
at presentation), and an index of clinical
performance status (asymptomatic or
minimal symptoms vs restricted activity
or confined to bed). This classification was
then applied to the 1st and 2nd MRC
myelomatosis trials, and confirmed the
usefulness of the classification over 5- and
11-year follow-up periods respectively.
PATIENTS AND METHODS
Patienits -with myelomatosis wvere entered
through 14 regional centres in the U.K. ToMRC WORKING PARTY ON LEUKAEMIA IN ADULTS
be eligible patients must not have been pre-
viously treated (except for local radiotherapy
or courses of corticosteroids) and must have
had at least 2 of the following 3 criteria at
presentation:
(i)
(ii)
(iii)
Marrow smears or sections showing
plasma-cell infiltration.
Skeletal X-rays with definite osteolytic
lesions.
A paraprotein in the serum and/or urine.
Patients were excluded if they had pre-
viously received cytotoxic therapy for any
condition, or were over 75 years of age.
Patients were treated with various cytotoxic
regimens, the details and effects of which are
reported elsewhere (MRC, 1980b). A total of
508 patients were entered into the trial
between 9 July 1975 and 4 August 1978. Of
these, 5 have been excluded as misdiagnosed,
7 exceeded the age limit of 75, and 4 remain
untraced. Records are incomplete in 7 further
cases, and do not permit prognostic grouping.
This leaves a total of 485 cases for which
prognostic factors can be assessed (Table I).
TABLE I.-Patient distribution
Total entered
Exclusions
Misdiagnosis
> 75 years
Untraced
Incomplete records
Total exclusions
Patients analysed
BUC < 10 mM
BUC > 10 mM
508
5
7
4
7
23 (4.5%)
485 (95.5%)
353 (73%)
132 (27%)
Follow-up is to 1 January 1980 and median
follow-up time is 36 months. By this date 276
(57%) deaths had occurred. Median survival
time is 21 months and 1- and 2-year survival
rates are 63% and 46% respectively. All life
tables are based on the actuarial method, and
significance levels are based on logrank
statistics. Relative death rates are defined as
the ratio of observed to "expected" deaths,
where expected deaths are calculated on the
null hypothesis that each death in a given
stratum is equally likely to have occurred in
any patient at risk at that time (cf. Peto et
al., 1976, 1977).
DATA COLLECTED
The following data were recorded by the
local centres at presentation: sex, age, height,
weight, haemoglobin, leucocyte count (total,
neutrophils, lymphocytes, plasma cells),
platelet count, ESR, alkaline phosphatase,
serum calcium, and uric acid levels. Blood
urea concentration (BUC) and serum creati-
nine levels were also requested both before
and, where relevant, after hydration. Sites
and numbers of sites of osteolytic deposits,
fractures, and soft-tissue masses were re-
corded. Albumin, paraprotein levels, and
polyclonal immunoglobin levels were meas-
ured, and heavy- and light-chain typing was
done centrally for 342 (70%) patients by the
Nuffield Department of Clinical Medicine,
Oxford (details in Leonard et al., 1979).
Paraprotein types for most of the remaining
patients were obtained from hospital records.
Urine proteins were measured by Professor
J. R. Hobbs. Other clinical observations were
also recorded, including a measure of per-
formance status (asymptomatic, minimal
symptoms, restricted activity, bedridden).
RESULTS
Prognostic groupings
Three factors in this study were shown
to be of far greater importance than any
ofthe others: these were measures ofrenal
function, haemoglobin and performance
status. After correcting for these 3 factors,
the other presenting features were found
to be of secondary value, either because
their effect on survival is much smaller or
because they occur in only a small propor-
tion of cases.
Prognostic significance ofgroupings
Renal function.-By far the strongest
predictors of survival are the indicators of
renal function. BUC and serum creatinine
levels were found to be equally good pre-
dictors of survival whether taken before
or after hydration. However, values after
hydration were much better predictors of
survival than prehydration values in both
cases (Tables II and IV). BUC values were
used for grouping because the data were
more complete.
Survival curves for the 4 groups of
patients whose post-hydration BUC levels
were < 8, 8-10, 10-16, > 16 mm are shown
in Fig. 1. When the post-hydration urea
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TABLE 11.-Major prognostic factors and
groupings. All x2 values are for trend
(I d.f.)
Variable
BUC (mm) before
hydration, x2 =60
BUC (mm) after
hydration, X2= 102
Haemoglobin (g/1),
x2=72
Performance status,
X2 = 39-9I
]
t
Concen-
tration
<-8
8-10
10-16
> 16
-8
8-10
10-16
> 16
> 100
75-100
--75
Minimal
symptoms
Restricted
activity
BUC and [Hb]
groups, x2 = 95 A
See text for groupings B
C
lelative No. of
death patients
rates (%)
0-72 246 (51)
1-01 56 (12)
1-07 86 (18)
2-36 94 (20)
0-77 336 (69)
1 11 40 (8)
1-56 56 (12)
3-68 53 (11)
0-68 248 (51)
1.19 145 (30)
2-15 92 (19)
0-64 193 (40)
1-34 292 (60)
0-61 213 (44)
0.91 116 (34)
2-08 156 (32)
Prognostic groupings,
x2=117 Good 0-41 105 (22)
Inter-
mediate 0-96 275 (56)
Poor 2-72 105 (22)
was lower than 8 mm there was no signifi-
cant improvementinsurvival, andpatients
in the 6-8 mM range fared only slightly
worse than those with values < 6 mm.
Although a renal function indicator using
both BUC and creatinine might give some
refinement, the effect is small, and con-
fined almost exclusively to reclassifying
patients whose BUC was <10 mm but
with high creatinine levels. Likewise,
studies based on the subset of patients
with complete urinary protein measure-
ments suggest that the improvements that
would be achieved by including these in
our index of renal dysfunction are likely
to be small.
Anaemia.-The second strongest prog-
nostic factor is anaemia. Survival curves
for the 3 groups of patients whose [Hb]
was < 75, 75-100, or > 100 g/l are shown
in Fig. 2. There is a surprisingly small
variation within groups; patients with
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Fia. 1 Duration of survival for groups of
patients with differing presentation values
of blood urea (after re-hydration, if neces-
sary). X2 (trend= 102, P < 0-0001. Number
of patients in each group given in paren-
theses.
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FIG. 2. Duration of survival for groups of
patients with differing presentation values
of haemoglobin. x2= 72, P< 0-0001.
[Hb] > 115 g/l fare no better than those in
the 100-115g/l range. There is also a
shallow survival gradient in the 75-100g/l
range. The prognostic significance of [Jib]
is largely independent of BUC levels
below 10 mM (Fig. 3a,b). Above that level
[Hb] appears to confer little further prog-
nostic information (Fig. 3c). The x2 value
(trend) for [Hb] after correcting for BUC
was 28-3, which is 39.4% of the uncor-
rected value (x2 = 71.8).
Performance status.-The final ingredi-
ant in the prognostic grouping is an
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FIG. 4. Duration of survival for asympto-
matic patients and patients with minimal
symptoms (combined) vs patients with
restricted activity or bedridden (combined).
x2 = 39 0, P < 0-0001.
TABLE III. Relative death rates for per-
formance status after correctingfor BUC
and [Hb] groups (No. of patients in
parentheses)
A. BUC < 8 mM
and [Hb] > 100 g/l
B. All others
C. BUC > 10 mM
or [Hb] < 75 g/l
Overall (corrected)
FIG. 3.-Duration of survival for groups of
patients with differing presentation values
of haemoglobin split according to blood
urea values: (a) BUC < 8 mm, x2 = 29-9,
P<0-0001. (b) BUC above 8 mm but not
greater than 10 mm, x2=4-21, P=0-04.
(c) BUC > 10 MM, x2= 1-31, P=0-25.
Minimal Re-
symp- stricted
toms activity
0-66
(105)
0-80
(40)
0-62
(48)
0-67
(193)
1-43
(108)
1-15
(76)
1-31
(108)
1-29
(292)
x2 foi stratum
15-1
P=0-0001
1-81
P=0-18
17-0
P < 0-0001
31-6
P < 0-001
estimate of clinical performance status.
A two-level indicator (asymptomatic or
minimal symptoms vs restricted activity
or bedridden) was used. Crude survival
curves are shown in Fig. 4. This variable
was independent of BUC and [Hb] levels,
and appeared to reflect the extent of
skeletal involvement. To test the inde-
pendence of performance status from
BUC and [Hb], the whole series was
divided into 3 groups based only on these
two variables:
Group A: BUC < 8 mM and [Hb] > 100 g/l.
Group B: all those not in A or C.
Group C: BUC > 10 mMor [Hb] < 75 g/l.
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The x2 for performance status after
stratification for these 3 groups is 31 6,
which is 81.10/ of the uncorrected value.
This variable was highly significant in
Groups A and C and showed a similar but
smaller effect in (hroup B (Table III).
Other factors were found to have lower
prognostic value, and for simplicity are
not considered for groupings. Based oni
these 3 variables, the following grouips
have beeni specified:
I G0ood prognosis: BUC < 8 mmd
II lIntermediate:
III Poor prognosis:
[Hb] > 100 g/l
and minimal symp-
toms or asympto-
matic.
All those not ill I or
III.
[Hb] < 75 g/l anid re-
stricted activity
or BUC > I O mM and
restricted activity
All BUC measurements are after hydra-
tion.
SUrIvival curves for these groups are
shown in Fig. 5. The large x2 value of 1I 7 1
intermnediate and poor prognosis groups
have 2-year survival probabilities of 76,
50 and 900 and contain 22, 56, 22% of
the patients respectively. Fturther sub-
division of the poor-prognosis patients is,
of course, possible, for example the sub-
group with BUC" > 16 mM showed a much
poorer survival than others in this group.
To verify the independent predictive
power of our prognostic groups we have
applied them to the patients in the 1st and
2nd trials. BUC was not always recorded
after rehydration in these trials and per-
formance status at presentation had to be
estimated retrospectively from the case
notes, so the results are not strictly com-
parable. However, the classificationi re-
mains powerful (Figs 6 & 7) and again
5
.z -5
*.0
Ii.~~~~~~~~~~~~~~~~~~.:
Fie'. D5.-Duiation of sunrival foiI patients inI
(liffe'l'ilig prognol stic' gi-OI)l. X-= 11 7 1,
1 <0 00()1.
5 :1 2 3 4
Fi( . -Duration of survival for patients
in (lifferinig prognostic groups in the
2ni(d MIRC Myelomatosis Trial. X2 =44 9
L> < 0(0001.
ZIO.O.
:.75.
'025-
O..' (1 d.f.) reflects to some extent the fact that
these same data were used to make the
classification, though the large sample size
and the simple diagnostic criteria make it
uinlikely to be greatly inflated. The good,
1 1 4 5f * V it1
' a m ' ~ ,. m*i~:;ig:i.b-a
1ie. 7. Duration of suii ixisal foiI patients inI
(lifferl'ilng prognostic gIrolups in tm I1st
1R(' Mlryelomatosi- Trial. X'= 530.
1' < 0(-(0)1.
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TABLE IV.-Otherprognosticfactors
Relative death
Level rate unstratified
Serum creatinine before
hydration (mM) < 100
100-150
> 150
x2
Scrum creatinine after
hydration (mM) < 100
100-150
> 150
x2
SeIum uric acid (mM) <0-3
0 3-0-6
> 0-6
x2
Platelets ( x 109/1) > 150
<150
x2
Leucocyte count (x 109/1) > 6-0
3 0-6-0
,<3 0
x2
Lymphocytes ( x 109/1) > 1-5
1-0-1-5
< 1-0
x2
Neutrophils (x 109/1) > 6-0
2-0-6 0
<2-0
x2
Plasma cells < 1%
> I%
x2
ESR (mm in first hour) < 70
70-100
> 100
x2
Age (yrs) <60
60-70
70-75
x2
Sex M
F
x2
Heavy-chain class G
A
Light chain
only
x2
(G or A) VS BJP
Light-chain type
Paraprotein level for
Class G (g/l)
x2
,<25
25-50
>50
x2
0-69
0-82
1-71
32.7,P<0-0001
0-71
0-85
2-24
51-5,P< 0-0001
0-62
1-00
2-46
36-8, P<0-0001
0-87
1-55
21-8,P < 0*0001
0-96
1-02
1-37
0-94
0-96
1-02
1-15
0-99
0-90
1-02
1-04
0-51
0-95
1-60
9-20, P= 0-003
0-71
0-83
1-20
14-0,P=0-002
0-94
1-04
1-06
0-71
1-13
0-88
4-89, P= 0-03
0-88
1-02
1-60
12-4, P=0-0004
0-96
1-06
0-65
1-13
0-92
1-04
0-06
Relative death
rate stratified
0*83
0-97
1-17
5*63,P=0*02
0*84
0*93
1*34
11*04,P=0-008
0-75
0-97
1-67
14-4, P=0-0001
0-91
1-31
9-13,P=0-003
0-97
1-04
0-99
0-27
1-05
0-87
1-05
0-33
0-81
1-09
0-85
0-32
0-95
1-52
7-42, P=0-006
0-86
0-83
1-11
3-98,P=0-05
0-99
1-01
1-00
0-02
1-16
0-86
6-90,P=0-01
0-93
0-95
1.46
8-18,P=0-004
0-94
1-12
2-03
1-10
0-92
1-05
0-02
Variable
No. of
patients
(%)
115 (34)
100 (30)
123 (36)
162 (48)
87 (26)
92 (27)
90 (24)
229 (62)
52 (14)
341 (75)
116 (25)
251 (53)
205 (43)
17 (4)
269 (61)
115 (26)
59 (13)
80 (18)
313 (70)
51 (12)
425 (90)
48 (10)
113 (26)
65 (15)
261 (59)
193 (40)
215 (44)
77 (16)
246 (51)
239 (49)
243 (56)
126 (30)
62 (14)
259 (62)
158 (38)
34 (24)
70 (50)
36 (26)
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TABLE IV. (cont.)
Variable I
Paraprotein level for
Class A (g/l)
IgM (g/1)
0-
Serum albumin (g/1)
Alkaline phosphatase (i.u.)
Relative death
Level rate unstratified
fi25
25-50
>50
x2
> 0 3
~-5-0-3
<0-O.15
x2
<30
30-40
>40
x2
<125
> 125
x2
Corrected serum
calcium* (mM) < 2-75
>2-75
x2
Total urinary pirotein (gll) < 0-85
Urinary albumin (g/l)
Osteolytic deposits
Fractures
Soft-tissue mass
0-85-2-0
> 2.0
x2
K,0.05
0-05-0.1
>0-1
x2
Absent
Present
x2
Absent
Present
x2
Absent
Present
x2
0 53
0-88
1-64
8-43,P= 0-004
0-80
0-84
1-34
7 90, P = 0 005
1-43
0 94
0-65
14-4,P=0-0001
0.95
1-25
4*03, P = 004
0-89
1-53
11-2, P= 0-0001
0 74
1-34
1-93
24-4, P = 0-0001
0-83
1-61
1-24
5-39,P=0-02
0-96
1-02
0-25
0 97
1-07
0-62
0-98
1-26
1-59
Relative death
rate stratified
0-56
0 90
1-49
6-31,P=0-02
0-80
0-82
1-37
8-95,P=0 003
1-15
0.99
0-76
3-72,P=0-06
0-97
1-13
1-25
0-94
1-23
2-90
0*79
1-24
1-55
12-5,P=0-0004
0-83
1-56
1-27
5-82, P = 0-02
1-03
0.99
009
0*99
1-01
0-02
0.99
1-17
1-75
Other possible prognostic features before and after prognostic grouping.
X2 for 1 d.f. unless otherwise indicated.
* Corrected Ca =Ca+ (36 Albumin (g/1l)) +/40.
about half the patients are in the good- or
poor-prognosis groups.
Other prognosticfactors
Other prognostic factors studied are
listed in Table IV.
Other renal factors-.The importance of
renal function is underscored by the fact
that variables related to it are the most
significant ofthe remaining variables after
prognostic grouping.
Levels of serum creatinine > 150 mm
retain some prognostic importance after
stratification. Levels of serum uric acid
> 0-6 mm are also important and show
greater independence from BUC values.
Total urinary protein remains highly sig-
nificant after stratification (P
= 0.004), as
are measurements of urinary albumin.
The relative death rates for the albumin
groups are almost unchanged by the
stratification.
Age and sex.-Age had little effect on
survival. This is in agreement with the
1st trial but differs from the report of the
2nd trial. This difference can be explained
satisfactorily by the age limit of 75 years
in the present trial, and the greater
No. of
patients
(%)
14 (17)
38 (47)
29 (36)
71 (28)
82 (32)
101 (40)
95 (30)
172 (43)
51 (16)
363 (79)
96 (21)
221 (72)
86 (28)
137 (63)
36 (17)
45 (20)
141 (65)
24 (16)
42 (19)
155 (33)
308 (67)
321 (69)
142 (31)
422 (91)
41 (9)
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natural mortali
longer follow-uj
ever, Matzner et
cases, found tha
above fared less
(P < 0.026).
TABLE V. Rela
each prognosti
parentheses)
Prognosis
Goodl
INterme(diate
Poor
Overall (corrected)
In this trial,
poorer response
(Table V). Thiv
significant both
(P=0-01) strati:
sition to the res
1973) in which a
ence could be fc
it is probable th
significance, the
the present trial
artefact of chanc
Thrombocytope
let counts below
prognosis. This e
across strata (Ta
independent of
examination of
TABLE VI. R
thrombocytope?
(No. ofpatient
1
Prognosis
Good
lntermediate
Poor
Overall (corrected)
ity associated with the patients with levels below 100 x 109/1
of the 2nd trial. How- fared no worse than those in the 100-150
al. (1978), in a series of 69 x 109/1 range. In fact, patients with
t patients of 60 years and counts in this lower range had a slightly
well than those below 60 better survival.
Leucocyte counts. Little prognostic in-
formation could be gleaned from total
ltive death rates for sex in leucocyte counts, lymphocyte or neutro-
c group (No. ofpatients in phil counts, in marked contrast to the
previously noted relevance of the red-
x2 for blood count. However, the presence of I % Mlale Female stratum or more plasma cellsin the blood indicated 1.15 0-84 0-92 poor survival, although the prognostic
-15 0-87 '3 usefulness is limited by its rareness (only (137) (138) 10% of patients presented with 10% or
1-17 0-85 2-48 more plasma cells in the blood). The effect
(54) (51) was unchanged by stratification.
1416 0586 6-90 Paraprotein types and levels ofpolyclonal
(246) (239) P=0-01 IgM.-Little difference in survival could
males showed a slightly be found between patients with Class G or
sachoweda pg sic ghtpy A paraproteins. There are too few cases to in each prognostic group permit comment on the survival of
before (Pw= 003) and after patients with paraproteins from the other befiorenP=i 0is3and
a r heavy-chain classes. However, patients fication. This is in oppo- with light-chain disease had a significantly
uales did better. No differ- worse prognosis. This difference holds even
)und in the 2nd trial, and after stratification, and the 14% of cases
at despite their statistical with only Bence Jones protein had a atpdespitentheffecto st ticl relative death rate of 1-60 (x2= 12.4) com- apparent effect of sex in pared to patients with either Class G or A I is wholly, or partly, an paraproteins before stratification, and a
vnea. Patietswitplate relative death rate of 1-78 (X2= 8l8) after nia. Patients with plate- stratification. The effect was most marked
fect again was consistent in good-prognosis patients (x2= 9.3) and
ible VI) and was partially still visible in the intermediate group
the groupings. Further (X2=3 34), but not very apparent in the
the data showed tFlat poor-prognosis group (x2= 1.13). A likely explanation is that the presence of a clone
'elative death rates for producing only Bence Jones protein is a
iaineachprognosticgrou-p risk factor for developing renal problems
ts in parentheses) at a later stage, although the records are not sufficiently detailed to verify this. This 'latelets5 xxlatelets result is in qualitative agreement with the
109/1 l09/1 stratum 1st stand 2nd MRC trials (MRC, 1973;
0-89 1-59 183 1980a) but conflicts with a report from
(80) (17) Leukaemia Group B (1975) suggesting that
0.91 1-38 4-48 IgA myeloma had a poorer survival than
(201) (57) IgG myeloma. Overall the two light-chain
086 124 310 types fared similarly, although K-type
0-90 132 9-0 patients showed slightly better survival
(341) (116) P = 0-003 after stratification. This was due to the
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better survival of K-type good-prognosis
patients (X2=5 55, P=002). The asso-
ciation of heavy and light chains was
almost exactly what would be expected
by chance, with a homogeneity test vield-
ing x2 of 0 83 (2 d.f.). Paraprotein and
polyclonal immunoglobulin levels were
only available for the 7000 of patients
whose samples were sent to a central
laboratory. Analysis of these cases pro-
duced no detectable effects of paraproteini
level in patients with IgG paraproteins: a
slightly worse prognosis prevailed for
patients with IgA paraproteins when their
level was > 50 g/l.
As in the 2nd trial. a clear gradient in
survival with polyclonal IgM levels was
apparent. This was little changed by the
stratification and was highly statistically
significant. A paradoxically high death
rate for patients with IgM > 05 g/l is
explained by 8 deaths in the first month
in this group. Four of these patients pre-
sented with BUC) levels > 10 mm and at
least 6 ofthem were known to have died in
renal failure.
Other serutm factors. Serum calcium
levels hlad only a small effect before
stratification, which was completely lost
afterwards. This agrees with the 1st MR(
trial, but is in sharp contrast to the strong
effects reported by Alexanian et al. (1975).
The effects of both serum albumin and
alkaline phosphatase were also completely
explained by the stratification.
Radiology. Osteolytic deposits, firac-
tures and soft-tissue masses appeared to
be of little prognostic significance.
I)ISCIJSSION
The total number of paraprotein-
secreting myeloma cells in the body, based
on direct, measurement of the rate of
secretion ofparaprotein by marrow plasma
cells in short-term cultture a,nd of the
serum concentration of paraprotein, was
measured by Salmon & Smith (1970). It,
was show%Nn that the numerical values of
several laboratory features recorded when
the estimate of tumour-cell number was
ma,de, varied in a systematic manner, so
that for each feature va,lues at one end of
the numerical range were associated with
low tumour-cell numbers and those at the
other end with high tumour-cell numbers.
Thus, it was possible to estimate whether a
patient would be in the high, low or inter-
mediate cell-mass group simply by record-
ing the numerical values of the features
previously found to correlate with the
calculation based on direct measurement?
of the rate of paraprotein secretion by the
myeloma cells in culture (Durie & Salmon,
1,975). It was further shown that the
survival of patients was inversely corre-
lated with the estimated total tumour-cell
mass. A better separation into good-
prognosis groups could be obtained by
combining the estimate of total tumour-
cell mass with an estimate of renal func-
tion, impaired renal ftinction being asso-
ciated with poor prognosis.
Although the work of Salmon & Smith
(1970) confirmed by Woodruff et al. (1979)
has clearly shown the prognostic import-
ance oftheir estimate oftumouir-cell mass,
it remains possible that, certain properties
of tumour cells mav have adverse effects
which can be measuired more directly than
through an estimate of the tumour-cell
mass, as is certainly the case, at least in
part, with the factor impairing renal
function. We therefore decided to ex-
amine empirically the prognostic signifi-
cance of features recorded at presentation,
to see whether it would be possible to
select combinations offeattures that would
identify patients with good or poor prog-
nosis. The value of such an attempt de-
pends on its ability to pick out good and
poor prognosis groups containing a sub-
stantial nuimber ofpatients with markedly
different prospects for survival. The
"good" and "poor" prognostic groups used
in this analysis each picked out 22%/O of
the 485 patients, and the probability of
survival for 2 years in these groups was
76% and °9%. By comparison, Alexanian
et al. (1975) used the 3 groups correspond-
ing to the high, intermediate and low
tumour-mass groups of Salmon, though
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the radiological findings, as used by
Salmon, could not be included. Twenty-
four per cent of the patients fell in the
low-tumour-mass group and 46% in the
high-mass group, and the probability of
survival for 2 years in these 2 groups was
76% and 33%.
Woodruff et al. (1979) also used these
groups. They found that 11% of the
patients were in the low-tumour-mass
group and 55% in the high-mass group
with 2-year survival probabilities of 85%
and 18%. If only patients treated with
melphalan or cyclophosphamide are in-
cluded, the group sizes change to 13% and
50%0 respectively. It is apparent that their
high-tumour-mass group contains patients
whom we would classify into the inter-
mediate prognosis group.
Thus, the discriminating power of the
groups we have chosen as a result of
empirical analysis compares favourably
with Salmon's groupings based on an
estimate of the tumour-cell mass. As
shown in Figs 6 & 7, the discriminating
power of our empirical groups holds when
they are applied to the 1st and 2nd MRC
Trials, with a much longer follow-up than
the 3rd trial.
In practice, the prognostic groups are
easy to apply because they are based on
readily available information and there is
little likelihood of error in recording the
clinical performance status, or oftechnical
unreliability in the measurement of [Hb]
or BUC.
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